Ability to sign informed consent.
Healthy male or female between 18-65 years of age.
Willing to have samples stored for future research.
History of an immune deficiency, such as HIV infection or cancer.
History of chronic hepatitis B and/or C infection.
History of chronic anemia.
A known clotting disorder or taking medications that interfere with blood clotting, such as: aspirin, heparin, or Coumadin*
Have taken an investigational drug in the last 6 months that may affect the normal process of blood cells.
Any condition that in the view of the principal investigator (PI) would make the subject unsuitable for enrollment in this study.
* Coumadin and/or heparin treatment will not be stopped so that a subject can participate in this protocol. If Coumadin or heparin was recently discontinued, a subject can be enrolled, but no bone marrow procedures will be performed until the PT and the PTT are within normal range. For other agents that interfere with blood clotting without prolonging the PT, a 7-day washout period will be required before bone marrow sampling.
(Procedure) EXCLUSION CRITERIA
Hemoglobin less than the NIH Clinical Center CRIS normal range.
Platelets less than 100,000/mm(3).
PT or PTT greater than the NIH Clinical Center CRIS normal range
EKG changes suggestive of cardiovascular disease.
Unable or unwilling to have bone marrow biopsy performed without use of conscious sedation, and use of only local anesthetic during procedure
Any other lab value which may put the subject at risk during the procedure.